Rodrigo Jorge

Professor Rodrigo Jorge holds a Scientific Initiation (1993) and a bachelor's degree (1994) from the Faculty of Medicine of Ribeirão Preto at the University of São Paulo (FMRP-USP). He completed his Ph.D. in Medicine, specializing in Ophthalmology at FMRP-USP (1999). In 2004, he passed a public examination for the position of Professor at the same faculty. In 2007, he earned the title of Livre-Docente at the Faculty of Medicine of Ribeirão Preto, becoming an Associate Professor. In 2022, he passed another public examination and became a Full Professor at the University of São Paulo. In 2023, he was elected Head of the Department of Ophthalmology, Otorhinolaryngology, and Head and Neck Surgery at FMRP-USP.Throughout his career, he specialized in Retina and Vitreous at the Escola Paulista de Medicina (1997-1998) and the Bascom Palmer Eye Institute (2001). He also specialized in Ocular Oncology at the Wills Eye Institute, Thomas Jefferson University, Philadelphia (2014), and in Pediatric Retina Surgery at the Associated Retinal Consultants, Royal Oak, Michigan (2019). He has experience in the field of Medicine, with an emphasis on Ophthalmology, focusing mainly on topics related to retinal diseases, ocular oncology, retinopathy of prematurity, macular diseases, diabetic retinopathy, diabetic macular edema, vitreoretinal surgery, combined retina and cataract surgeries, macular surgeries (macular hole and epiretinal membrane), age-related macular degeneration, optical coherence tomography, anti-angiogenic drugs (ranibizumab, bevacizumab, aflibercept), triamcinolone, and prolonged drug release.In 1998, he founded the Retina and Vitreous Service at HCFMRP-USP and has contributed to the training of 72 Retina and Vitreous specialists, 9 master's students, 24 doctoral students, and 4 postdoctoral students. In 2015, he founded the Ocular Oncology Service at HCFMRP-USP and established treatment for Retinoblastoma and Choroidal Melanoma with brachytherapy through the public healthcare system (SUS) in the Ribeirão Preto region. He has trained 4 specialists in Ocular Oncology and supervised one doctoral thesis in this subspecialty.In research, he is part of the INOVASENSE Research and Pharmaceutical Innovation Group at CNPq, collaborating with professors from the Federal University of Minas Gerais and the Ezequiel Dias Foundation. He was responsible for the first human procedure involving intravitreal implantation of an antibiotic for treating ocular toxoplasmosis and the first intravitreal implant in humans of a carbonic anhydrase inhibitor for treating macular edema. In ocular oncology, he pioneered the first combined treatment using chemotherapy and ruthenium brachytherapy for primary choroidal melanoma.In 2023, he was ranked among the top 5 Ophthalmology Researchers in Latin America by the AD Scientific Index. In 2024, he was accepted as a member of the Macula Society, becoming the fifth Brazilian in history to be accepted into this American society. (Source: Lattes Curriculum)